{"product_id":"staar-swot-analysis","title":"STAAR Surgical SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSTAAR Surgical's innovative lens technology presents a significant strength, but understanding the full scope of their market challenges and opportunities requires a deeper dive. Our comprehensive SWOT analysis reveals critical insights into their competitive landscape and potential growth avenues.\u003c\/p\u003e\n\u003cp\u003eWant to truly grasp STAAR Surgical's position? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support your strategic planning and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Phakic IOLs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical holds a commanding position as the world's leading provider of phakic intraocular lenses, a distinction primarily driven by its highly regarded EVO family of Implantable Collamer® Lenses (ICLs). This market dominance is the result of sustained focus on ophthalmic surgery for decades and a wide-reaching distribution network spanning over 75 countries.\u003c\/p\u003e\n\u003cp\u003eThe company's success is further evidenced by its impressive sales figures, having distributed more than 3 million ICLs globally. This substantial volume underscores strong market acceptance and STAAR Surgical's significant penetration within the vision correction sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology and Clinical Efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical's proprietary Collamer material is a significant strength, providing a unique biocompatible lens with a built-in UV filter. This material allows for excellent vision quality without the need to remove corneal tissue, setting it apart from other refractive surgery options.\u003c\/p\u003e\n\u003cp\u003eThe clinical efficacy of STAAR's EVO ICLs is consistently demonstrated through robust studies. A 2024 study reported an impressive 99% patient satisfaction rate, underscoring the safety and effectiveness of the technology. This strong clinical validation builds considerable confidence among both surgeons and patients regarding the procedure's outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinimally Invasive and Reversible Procedure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe EVO ICL stands out by being a minimally invasive and reversible procedure, a significant differentiator from laser surgeries like LASIK. This lens-based approach preserves the patient's natural cornea, making it an ideal solution for individuals with thin corneas or dry eye conditions who might otherwise be excluded from refractive surgery options.\u003c\/p\u003e\n\u003cp\u003eThis characteristic significantly expands STAAR Surgical's addressable market by catering to a patient segment actively seeking alternatives that do not involve corneal alteration. This focus on preserving corneal health is a key strength, particularly as patient awareness and demand for less invasive treatments grow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Performance Outside China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTAAR Surgical's performance outside of China remains a significant strength, showcasing resilience and broad market appeal. In fiscal year 2024, implantable Collamer Lens (ICL) sales, excluding the Chinese market, saw a healthy 13% increase. This upward trend continued into the first quarter of 2025, with sales in these same regions growing by 9%.\u003c\/p\u003e\n\u003cp\u003eThis consistent double-digit growth in diverse international markets highlights effective market penetration and strong consumer demand for STAAR's products beyond its primary Asian focus. Such geographical diversification is crucial for mitigating risks associated with economic fluctuations or regulatory changes in any single country, providing a more stable revenue base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRobust International Growth:\u003c\/strong\u003e ICL sales outside China grew 13% in FY2024 and 9% in Q1 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Diversification:\u003c\/strong\u003e Strong performance in multiple global regions reduces reliance on any single market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDemand Validation:\u003c\/strong\u003e Consistent growth validates the global appeal and effectiveness of STAAR's ICL technology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Innovation and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTAAR Surgical demonstrates a strong commitment to innovation, consistently increasing its research and development expenditures. For instance, in the first quarter of 2024, R\u0026amp;D expenses rose to $30.9 million, reflecting a dedication to advancing its implantable collamer lens (ICL) technology. This investment fuels the development of new products, such as the EVO Viva lens designed to address presbyopia, showcasing a forward-looking approach to meeting evolving patient needs.\u003c\/p\u003e\n\u003cp\u003eBeyond product development, STAAR Surgical places significant emphasis on surgeon education and training. Initiatives like STAAR University and the EVO Experience Center are crucial for building clinical confidence and driving the adoption of its ICLs. This focus ensures surgeons are well-equipped to utilize the latest advancements, ultimately benefiting patient outcomes and expanding market penetration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased R\u0026amp;D Investment:\u003c\/strong\u003e Q1 2024 R\u0026amp;D expenses reached $30.9 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Innovation:\u003c\/strong\u003e Development of EVO Viva lens for presbyopia.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSurgeon Education:\u003c\/strong\u003e Programs like STAAR University and EVO Experience Center.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Adoption:\u003c\/strong\u003e Fostering clinical confidence to drive ICL usage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Vision Correction: Global Leadership and Patient Satisfaction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical's leading position in the phakic intraocular lens market, particularly with its EVO ICLs, is a significant strength. The company's extensive global distribution network, reaching over 75 countries, combined with over 3 million ICLs distributed, highlights its market penetration and broad acceptance. The proprietary Collamer material offers unique biocompatibility and UV protection, enhancing vision quality without corneal alteration.\u003c\/p\u003e\n\u003cp\u003eThe EVO ICL procedure's minimally invasive and reversible nature is a key differentiator, preserving the natural cornea and expanding the addressable market to patients unsuitable for laser surgery. Clinical validation, such as a 99% patient satisfaction rate reported in a 2024 study, further bolsters surgeon and patient confidence in the technology's safety and efficacy.\u003c\/p\u003e\n\u003cp\u003eSTAAR's financial performance outside of China demonstrates resilience, with ICL sales in these regions growing 13% in fiscal year 2024 and 9% in the first quarter of 2025. This consistent growth across diverse international markets validates the global appeal of its ICL technology and provides a stable revenue base.\u003c\/p\u003e\n\u003cp\u003eThe company's commitment to innovation is evident in its increased R\u0026amp;D spending, with Q1 2024 R\u0026amp;D expenses reaching $30.9 million, supporting the development of new products like the EVO Viva lens for presbyopia. Furthermore, robust surgeon education programs, including STAAR University, drive market adoption and clinical confidence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003cth\u003eQ1 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eICL Sales Growth (Ex-China)\u003c\/td\u003e\n\u003ctd\u003e13%\u003c\/td\u003e\n\u003ctd\u003e9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Satisfaction (EVO ICL)\u003c\/td\u003e\n\u003ctd\u003e99% (2024 Study)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e$30.9 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal ICLs Distributed\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3 million\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes STAAR Surgical’s competitive position through key internal and external factors, highlighting its market strengths, operational gaps, and potential threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a clear, actionable framework to identify and address STAAR Surgical's key challenges and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Dependency on China Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical's significant reliance on the Chinese market presents a notable weakness. This dependency exposes the company to substantial macroeconomic headwinds and declining consumer confidence, as seen in China. For instance, the company reported significant revenue declines in China during Q4 2024 and Q1 2025. This downturn was attributed to distributors reducing their existing inventory levels and a weakening demand for elective, cash-pay medical procedures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscretionary and Premium Product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical's reliance on its implantable collamer lenses (ICLs) as a cash-paid, discretionary, and premium product makes it particularly vulnerable to economic headwinds.  When consumer spending tightens, as it did during periods of economic uncertainty in 2023 and early 2024, demand for non-essential, high-cost procedures like ICLs can significantly dip. This sensitivity to consumer confidence means sales can fluctuate unpredictably, impacting the company's revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecent Financial Losses and Outlook Withdrawal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical experienced a significant financial setback, reporting a net loss of $(20.2) million for the fiscal year 2024. This downward trend continued into the first quarter of fiscal year 2025, with a substantial net loss of $(54.2) million. \u003c\/p\u003e\n\u003cp\u003eThis financial performance prompted the company to withdraw its revenue guidance for fiscal year 2025. Consequently, STAAR Surgical no longer anticipates meeting its previously set Vision 2026 Target Sales and Operating Model. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecreased Gross Margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSTAAR Surgical's gross profit margin has experienced a noticeable dip. For fiscal year 2024, it fell to 76.3%, down from 78.4% in 2023. This trend continued into the first quarter of 2025, with the margin declining further to 65.8%.\u003c\/p\u003e\n\u003cp\u003eSeveral factors contribute to this margin compression. These include lower overall sales, a rise in operating expenses, and an increase in manufacturing costs per unit. The higher per-unit costs are a direct result of reduced production volumes and recent investments made in new facilities, impacting efficiency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDecreased Gross Margin:\u003c\/strong\u003e Dropped to 76.3% in FY2024 from 78.4% in FY2023, and 65.8% in Q1 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eContributing Factors:\u003c\/strong\u003e Lower sales, increased operating expenses, and higher manufacturing costs per unit.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCost Drivers:\u003c\/strong\u003e Reduced production volumes and investments in new facilities are key drivers of higher per-unit costs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImpact:\u003c\/strong\u003e This margin compression poses a challenge to the company's overall profitability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Product Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSTAAR Surgical's revenue stream is heavily concentrated, with implantable Collamer Lenses (ICLs) accounting for virtually all of its sales, around 100% in fiscal year 2024. This extreme focus, while enabling deep specialization in the ICL market, inherently limits the company's product diversification. Such a narrow product portfolio exposes STAAR Surgical to significant risks if market preferences for ICLs shift or if newer, competing technologies emerge that render their core product obsolete.\u003c\/p\u003e\n\u003cp\u003eThis lack of diversification presents a notable weakness:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Concentration:\u003c\/strong\u003e STAAR Surgical's reliance on ICLs for nearly all its revenue (approximately 100% in FY2024) makes it highly susceptible to market dynamics affecting this single product category.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVulnerability to Competition:\u003c\/strong\u003e A singular focus on ICLs leaves the company exposed to the potential for disruptive technologies or a significant shift in patient or surgeon preferences away from this specific type of vision correction.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLimited Growth Avenues:\u003c\/strong\u003e Without a broader range of products or services, STAAR Surgical's opportunities for organic growth are largely confined to expanding its ICL market share rather than capitalizing on new market segments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial downturn: China reliance, ICL dependency, and mounting losses.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical's heavy reliance on the Chinese market is a significant vulnerability. The company's revenue saw a notable decline in China during Q4 2024 and Q1 2025, driven by distributors reducing inventory and weaker demand for elective procedures. This dependency makes STAAR susceptible to the region's economic fluctuations and shifts in consumer spending, as evidenced by the downturn in early 2024.\u003c\/p\u003e\n\u003cp\u003eThe company's financial performance in 2024 and early 2025 highlighted significant weaknesses. STAAR Surgical reported a net loss of $(20.2) million for fiscal year 2024 and an even larger loss of $(54.2) million in Q1 2025. This led to the withdrawal of their 2025 revenue guidance and the acknowledgment that their Vision 2026 targets would not be met.\u003c\/p\u003e\n\u003cp\u003eSTAAR's gross profit margin has also eroded, dropping to 76.3% in FY2024 from 78.4% in FY2023, and further to 65.8% in Q1 2025. This compression stems from lower sales, increased operating expenses, and higher per-unit manufacturing costs, exacerbated by reduced production volumes and recent facility investments.\u003c\/p\u003e\n\u003cp\u003eA critical weakness is STAAR Surgical's near-total dependence on implantable Collamer Lenses (ICLs), which accounted for approximately 100% of its revenue in FY2024. This lack of product diversification leaves the company exposed to potential shifts in market preferences or the emergence of competing technologies, limiting its growth avenues beyond expanding ICL market share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2023\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003cth\u003eQ1 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e$(20.2) million\u003c\/td\u003e\n\u003ctd\u003e$(54.2) million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e78.4%\u003c\/td\u003e\n\u003ctd\u003e76.3%\u003c\/td\u003e\n\u003ctd\u003e65.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Concentration (ICLs)\u003c\/td\u003e\n\u003ctd\u003e~100%\u003c\/td\u003e\n\u003ctd\u003e~100%\u003c\/td\u003e\n\u003ctd\u003e~100%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eSTAAR Surgical SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual STAAR Surgical SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. You can trust that the insights and structure you see here are representative of the complete, detailed report.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full STAAR Surgical SWOT report you'll get. Purchase unlocks the entire in-depth version, providing a comprehensive understanding of the company's strategic position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610683130233,"sku":"staar-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/staar-swot-analysis.png?v=1754743803","url":"https:\/\/growthsharematrix.com\/products\/staar-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}